Literature DB >> 15257941

NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).

Carrie Fidler, Fiona Watkins, David T Bowen, Timothy J Littlewood, James S Wainscoat, Jacqueline Boultwood.   

Abstract

Mutations of the NRAS and TP53 genes and internal tandem duplication (ITD) of the FLT3 gene are among the most frequently observed molecular abnormalities in the myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). We sought to determine the incidence of these abnormalities in patients with MDS and a 5q deletion. NRAS and FLT3 mutations are uncommon in MDS patients with a 5q deletion and TP53 mutation is associated with the more advanced MDS subtypes.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15257941

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  11 in total

1.  Mutations of ASXL1 and TET2 in aplastic anemia.

Authors:  Jinbo Huang; Meili Ge; Shihong Lu; Jun Shi; Xingxin Li; Jizhou Zhang; Min Wang; Wei Yu; Yingqi Shao; Zhendong Huang; Jing Zhang; Neng Nie; Yizhou Zheng
Journal:  Haematologica       Date:  2015-01-16       Impact factor: 9.941

2.  Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited.

Authors:  Andres Jerez; Lukasz P Gondek; Anna M Jankowska; Hideki Makishima; Bartlomiej Przychodzen; Ramon V Tiu; Christine L O'Keefe; Azim M Mohamedali; Denise Batista; Mikkael A Sekeres; Michael A McDevitt; Ghulam J Mufti; Jaroslaw P Maciejewski
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

3.  Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice.

Authors:  Tim H-P Chen; Amal Kambal; Kilannin Krysiak; Mark A Walshauser; Gagan Raju; Justin F Tibbitts; Matthew J Walter
Journal:  Blood       Date:  2010-12-01       Impact factor: 22.113

4.  Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.

Authors:  Marta Fernandez-Mercado; Adam Burns; Andrea Pellagatti; Aristoteles Giagounidis; Ulrich Germing; Xabier Agirre; Felipe Prosper; Carlo Aul; Sally Killick; James S Wainscoat; Anna Schuh; Jacqueline Boultwood
Journal:  Haematologica       Date:  2013-07-05       Impact factor: 9.941

5.  Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis.

Authors:  Andres Jerez; Yuka Sugimoto; Hideki Makishima; Amit Verma; Anna M Jankowska; Bartlomiej Przychodzen; Valeria Visconte; Ramon V Tiu; Christine L O'Keefe; Azim M Mohamedali; Austin G Kulasekararaj; Andrea Pellagatti; Kathy McGraw; Hideki Muramatsu; Alison R Moliterno; Mikkael A Sekeres; Michael A McDevitt; Seiji Kojima; Alan List; Jacqueline Boultwood; Ghulam J Mufti; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2012-05-02       Impact factor: 22.113

6.  Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).

Authors:  M Mossner; J-C Jann; D Nowak; U Platzbecker; A Giagounidis; K Götze; A Letsch; D Haase; K Shirneshan; F Braulke; R F Schlenk; T Haferlach; P Schafhausen; G Bug; M Lübbert; A Ganser; G Büsche; E Schuler; V Nowak; J Pressler; J Obländer; S Fey; N Müller; E Lauinger-Lörsch; G Metzgeroth; C Weiß; W-K Hofmann; U Germing; F Nolte
Journal:  Leukemia       Date:  2016-05-02       Impact factor: 11.528

7.  NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes.

Authors:  D M Murphy; R Bejar; K Stevenson; D Neuberg; Y Shi; C Cubrich; K Richardson; P Eastlake; G Garcia-Manero; H Kantarjian; B L Ebert; G Mike Makrigiorgos
Journal:  Leukemia       Date:  2013-05-27       Impact factor: 11.528

8.  Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.

Authors:  Martin Jädersten; Leonie Saft; Andrea Pellagatti; Gudrun Göhring; James S Wainscoat; Jacqueline Boultwood; Anna Porwit; Brigitte Schlegelberger; Eva Hellström-Lindberg
Journal:  Haematologica       Date:  2009-10-01       Impact factor: 9.941

Review 9.  Recent Advances in the 5q- Syndrome.

Authors:  Andrea Pellagatti; Jacqueline Boultwood
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-05-20       Impact factor: 2.576

10.  TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes.

Authors:  Monika Belickova; Jitka Vesela; Anna Jonasova; Barbora Pejsova; Hana Votavova; Michaela Dostalova Merkerova; Zuzana Zemanova; Jana Brezinova; Dana Mikulenkova; Marie Lauermannova; Jan Valka; Kyra Michalova; Radana Neuwirtova; Jaroslav Cermak
Journal:  Oncotarget       Date:  2016-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.